The TGA
Federal · Australia · 201-500 Employees
View Company Info for Free
Overview
Headquarters
PO Box 100, Woden, Australian Capital Te...Phone Number
+61 1800020653Website
www.tga.gov.auRevenue
$18.5 MillionIndustry
About The TGA
The TGA Org Chart
Branch Manufacturing Quality Branch Head
Head Manager
Director
Director
Director
Director
Director, Regulatory Outcomes Stream
Director
Director
Is The TGA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on The TGA recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at The TGA
The TGA, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when The TGA launches new products
Click to see if The TGA had a recent Job posting/layoffs
Check if The TGA has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once The TGA has new funding data
Check out if The TGA is spiking on competitors!
Recommended Actions
Find VP level buyers at The TGA
Find more new buyers
Compare Similar Companies to The TGA
Compare insights from companies similar to The TGA, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
The TGA is experiencing very low activity levels compared to other companies in the Government sector.
What does this means?
The TGA is drawing exceptional interest within the Government industry, suggesting notable developments or strong market momentum, learn more about The TGA.
The TGA Tech Stack
A closer look at the technologies used by The TGA
The TGA News & Media
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours TGA registration provides an approved treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapy AMSTERDAM, May 6, 2026 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company is pleased to announce that PEDMARQSI® (sodium thiosulNew First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2] Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval...MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2...NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA
SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1] SINGAPORE, May 29, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce...
Top Federal Companies
Frequently Asked Questions Regarding The TGA
The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for therapeutic goods. They carry out a range of assessment and monitoring activities to ensure therapeutic goods available in Australia are of an acceptable standard to ensure that the Australian community has access, within a reasonable time, to therapeutic advances. T... Read More